Arkolith/Insider Trading/CRNX/Form 4

Fust Matthew K

DirectorCrinetics Pharmaceuticals, Inc. (CRNX) · full profile →Form 4 · filed Sep 30, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$716K
Net Open-Market Flow
-$716K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 26, 2025Sell(S)16K$44.75$716K23K
Sep 26, 2025Option exercise(M)10K$1.91$19K39K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 26, 2025Option exercise(M)10K—$02K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001658247-25-000010) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML